Abstract
The incidence of premature ovarian insufficiency (POI) is increasing in the general population with, among other reasons, more women surviving cancer treatments or having risk-reducing prophylactic oophorectomy due to BRCA status. The ovary is a vital endocrine gland and lost hormones need replacing to maintain system-wide health until the average age of the menopause (51 years). The combined oral contraceptive or hormone replacement therapy are recognised treatment choices for POI, but choosing the individual prescription may seen daunting. Through simple risk–benefit assessment and understanding modes of action, the nurse prescriber can guide effective decision-making and support long-term compliance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.